Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Esculin is a natural hydroxycoumarin glycoside found in horse chestnut and other plants. It is the 6-O-beta-D-glucoside of esculetin. Esculin has been used as a vasoprotective agent to improve capillary permeability and fragility, and it exhibits antioxidant, anti-inflammatory, and potential anti-cancer properties[2][3][4][5][8]. Its mechanism of action includes inhibition of catabolic enzymes such as hyaluronidase and collagenase (preserving perivascular connective tissue), direct antioxidant effects, modulation of oxidative stress-related enzyme activities (such as SOD and GSH), attenuation of NF-κB signaling activity, promotion of PPAR-γ nuclear localization[4][5], and inhibition of the PI3K/Akt pathway in cancer cells[6]. Esculin is also used in microbiology for bacterial identification due to its hydrolysis by certain bacteria[2]. Oral bioavailability is low (~0.62%), but it can be absorbed when applied to open wounds or mucosa[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on esculin.